Dupilumab Cuts Food Allergy IgE Levels in Small Study: Daily Dose

Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.

On February 28, 2025, we reported on a retrospective study presented at the 2025 American Academy of Allergy, Asthma, & Immunology Annual Meeting that was designed to examine whether dupilumab influences immunoglobulin E (IgE) levels in individuals with comorbid food allergies.

The study

The study included 13 adults at Deaconess Clinic Allergy in Evansville, IN, with documented food allergies who were prescribed dupilumab. Each participant had at least 2 measured IgE levels before initiating dupilumab and at least 1 measurement taken more than 2 months after starting treatment. A total of 77 allergens were analyzed. Investigators assessed IgE level changes over time, with follow-up measurements extending up to 84 months after dupilumab initiation.

The findings

At 12 months, IgE levels decreased by 56.9% (P <.001; n = 71), and at 24 months by 73.5% (P < .001; n = 37). Notably, patients who successfully passed oral food challenges exhibited a 69.4% reduction at 12 months (P =.012) and an 81.8% reduction at 24 months (P = .027).

Authors' comments

"Dupilumab was associated with reduction of specific IgE to foods at 12 and 24 months as well as passed food challenge in this retrospective study."

Click here for more details.